Health Care·Biotechnology·$2.2B
BioCryst Pharmaceuticals (BCRX) is a biotechnology company focused on developing innovative treatments for rare diseases. With a market cap of $2 billion, the company is part of the healthcare sector and plays a crucial role in addressing unmet medical needs through its specialized therapies.
EPS
Earnings per share (EPS) is a key indicator of the company's profitability and financial health.
Revenue
Revenue figures provide insight into the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
4Q
EPS Beat Rate
75%
Avg EPS Surprise
+290.32%
Avg Stock Reaction
+4.29%
In the last quarter, BioCryst reported an impressive EPS of $1.12, significantly exceeding expectations. The stock saw a positive reaction, gaining 4.64% the following day.
Management Promises & Guidance
Analysts expect BioCryst to report strong earnings this quarter, with a consensus EPS of $0.11 and revenue of $151 million. The company has a history of beating earnings expectations, which could lead to positive market reactions.
Bull Case
If BioCryst exceeds the EPS and revenue estimates, it could reinforce investor confidence and lead to a significant stock price increase, similar to past performance.
Bear Case
Conversely, if the company fails to meet expectations, it may trigger a sell-off, reflecting investor concerns about its growth trajectory and market position.
EPS
$0.11Earnings per share (EPS) is a key indicator of the company's profitability and financial health.
Revenue
$151MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will BioCryst achieve an EPS of at least $0.11?
This EPS figure is critical as it reflects the company's profitability and could significantly influence investor sentiment.
Q2
What are the revenue figures for this quarter?
Revenue performance will indicate market demand for BioCryst's products and its ability to grow sales, impacting future projections.
Why consensus could be wrong
The Street may be underestimating BioCryst's ability to exceed expectations based on its recent strong performance and market positioning.
Supporting Evidence
The company has consistently beaten EPS estimates in recent quarters, indicating strong operational execution.
Options pricing suggests a significant expected move, reflecting heightened investor interest and potential for positive surprises.
Key Risk
If revenue comes in below $142 million, it could undermine confidence in the company's growth prospects.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will either validate the company's growth trajectory or signal potential challenges ahead.
Bull Confirmed If
An EPS of $0.14 or higher would confirm strong demand and operational effectiveness.
Bear Confirmed If
An EPS below $0.10 would raise concerns about the company's growth and market position.
Implied Move
±12.8%
Historical Avg
±11.6%
The options market is pricing in a significant move of approximately 12.8%, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±12.8% while BCRX has averaged ±11.6% over the last 8 prints — setup is roughly in line with history.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If BioCryst beats expectations, history suggests the stock could rise by around 9.5%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.
Miss
A miss could lead to a decline of approximately 11.4%, reflecting investor disappointment and concerns about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026